Although the evidence suggests that targeting MEK may increase tumor immunogenicity, potentially allowing for greater TIL infiltrate, MEKi has also been shown to adversely affect anti-tumor immunity23, 25, 38. This evidence concerns the gene MAP2K7 and neoplasm.